<SEC-DOCUMENT>0001564590-21-017811.txt : 20210406
<SEC-HEADER>0001564590-21-017811.hdr.sgml : 20210406
<ACCEPTANCE-DATETIME>20210406161304
ACCESSION NUMBER:		0001564590-21-017811
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210402
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210406
DATE AS OF CHANGE:		20210406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		21809314

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-8k_20210402.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20210402.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:justify;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="color:#000000;font-size:12pt;"> </font><font style="color:#000000;">April 6, 2021 (April 2, 2021)</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10170 Church Ranch Way, Suite 100, Westminster, CO</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">80021</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (720) 940-2200</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:12pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:86.67%;">
<tr>
<td style="width:25.83%;"></td>
<td style="width:20%;"></td>
<td style="width:40.83%;"></td>
</tr>
<tr style="height:12.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:16.6pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABIO</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Capital Market</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:justify;margin-top:4pt;border-top:Solid 0.75pt #000000;padding-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="P280769376"></a>Item 1.01.</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Entry Into a Material Definitive Agreement.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 6, 2021, ARCA biopharma, Inc. (the &#8220;Company&#8221;) entered into Amendment No. 1 (the &#8220;Amendment&#8221;) to its Capital on Demand<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Sales Agreement dated July 22, 2020 (the &#8220;Original Agreement&#8221;), (together, the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent or principal (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell, from time to time through or to the Agent, additional shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Shares&#8221;), having an aggregate offering price of up to $50,000,000 (the &#8220;Offering&#8221;). The Company will file a prospectus supplement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with the Offering (the &#8220;Prospectus Supplement&#8221;) under its existing Registration Statement on Form S-3 (File No.&#160;333&#8209;254585), which became effective on March&#160;30,&#160;2021 (the &#8220;Registration Statement&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="S116575981"></a>Under the Sales Agreement, the Agent may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company may instruct the Agent not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not obligated to make any sales of the Shares under the Sales Agreement. The Company or the Agent may suspend or terminate the Offering upon notice to the other party and subject to other conditions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay the Agent a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and has agreed to provide the Agent with customary indemnification and contribution rights. The Company also agreed to reimburse the Agent for certain specified expenses in connection with entering into the Sales Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form&#160;8-K&#160;and is incorporated herein by reference. The Company previously filed the Original Agreement as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on July 22, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP, counsel to the Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Shares will be sold pursuant to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus Supplement and any accompanying prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction<font style="color:#000000;">.</font> </p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 5.08. Shareholder Director Nominations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 2, 2021, the board of directors (the &#8220;Board&#8221;) of ARCA biopharma, Inc., a Delaware corporation (the &#8220;Company&#8221;), approved June 10, 2021 as the date of the Company&#8217;s 2021 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). The Board also approved April 9, 2021 as the record date for stockholders entitled to notice of and to vote at the Annual Meeting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the fact that the Annual Meeting will be held more than 30 calendar days from the date of the Company&#8217;s 2020 Annual Meeting of Stockholders, the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and the bylaws of the Company listed in the Company&#8217;s 2020 Proxy Statement on Schedule 14A as filed with the SEC on October 28, 2020 are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no later than April 11, 2021. The Company currently intends to make its proxy materials available beginning on or about April 21, 2021<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;">&nbsp;</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9 &#8212; Financial Statements and Exhibits </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:87.5%;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex51_7.htm"><font style="text-decoration:underline;">Opinion of Cooley LLP</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex101_6.htm"><font style="text-decoration:underline;">Amendment No. 1 to Capital on Demand</font><font style="font-size:8.5pt;text-decoration:underline;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="text-decoration:underline;">&#160;Sales Agreement, dated April 6, 2021, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex51_7.htm"><font style="text-decoration:underline;">Consent of Cooley LLP (included in Exhibit 5.1).</font></a></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: April 6, 2021</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>abio-ex51_7.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex51_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaavqm1vj4rf000001.jpg" title="" alt="" style="width:136px;height:44px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45.38%;">
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brent D. Fassett</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 720 566 4025</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bfassett@cooley.com</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:54.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2021</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.<br />10170 Church Ranch Way, Suite 100<br />Westminster, Colorado 80021</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M7"></a><a name="_DV_M7"></a>Ladies and Gentlemen:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M12"></a><a name="_DV_M17"></a><a name="_DV_M15"></a><a name="_DV_M16"></a>You have requested our opinion, as counsel to ARCA biopharma, Inc.<font style="color:#000000;">, a Delaware corporation (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Company</font><font style="color:#000000;">&#8221;), with respect to certain matters in connection with the offering by the Company of up to $50,000,000</font> <font style="color:#000000;">of the Company&#8217;s common stock, par value $0.001 (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Shares</font><font style="color:#000000;">&#8221;), pursuant to a<a name="_DV_M12"></a> Registration Statement on Form S-3 (No. 333-254585) (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Registration Statement</font><font style="color:#000000;"><a name="_DV_M17"></a>&#8221;)<a name="_DV_M15"></a>, filed with the Securities and Exchange Commission (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commission</font><font style="color:#000000;">&#8221;<a name="_DV_M16"></a>) under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Act</font><font style="color:#000000;">&#8221;), the prospectus included in the Registration Statement (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Base Prospectus</font><font style="color:#000000;">&#8221;), and the prospectus supplement dated April 6, 2021, filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Prospectus</font><font style="color:#000000;">&#8221;) The Shares are to be sold by the Company in accordance with a Capital on Demand&#8482;</font><font style="font-weight:bold;color:#000000;"> </font>Sales Agreement, dated July 22, 2020, between the Company and JonesTrading Institutional Services LLC, as amended (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;)<font style="color:#000000;">, as described in the Prospectus.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this opinion, we have examined and relied upon the Registration Statement and the Prospectus, the Agreement, the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, and Second Amended and Restated Bylaws, as amended, and originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. In rendering this opinion, we have assumed the genuineness of all signatures; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof.&nbsp;&nbsp;As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assumed (i) that each sale of Shares will be duly authorized by the Board of Directors of the Company, a duly authorized committee thereof or a person or body pursuant to an authorization granted in accordance with Section 152 of the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight:bold;font-style:italic;">DGCL</font>&#8221;), (ii) that no more than 11,111,111<font style="color:#000000;"> </font>Shares will be sold under the Agreement after the date hereof and (iii) that the price at which the Shares are sold will equal or exceed the par value of the Shares.&nbsp;&nbsp;We express no opinion to the extent that future issuances of securities of the Company and/or anti-dilution adjustments to outstanding securities of the Company cause the number of shares of the Company&#8217;s common stock outstanding or issuable upon conversion or exercise of outstanding securities of the Company to exceed the number of Shares then issuable under the Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our opinion herein is expressed solely with respect to the DGCL.&nbsp;&nbsp;Our opinion is based on these laws as in effect on the date hereof.&nbsp;&nbsp;We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </p>
<p style="margin-top:12pt;text-align:center;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="zzmpFIXED_LHFirstPageFooter_Text"></a><a name="zzmpFIXED_LHFirstPageFooter_Text"></a> Cooley LLP&nbsp;&nbsp; 380 Interlocken Crescent&nbsp;&nbsp; Suite 900&nbsp;&nbsp; Broomfield, CO&nbsp;&nbsp; 80021-8023<br />t: (720) 566-4000&nbsp;&nbsp;f: (720) 566-4099&nbsp;&nbsp;cooley.com</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:3.45pt;">
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaavqm1vj4rf000001.jpg" title="" alt="" style="width:136px;height:44px;"></p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.45pt;">
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr style="height:26pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page Two</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.15%;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the foregoing, and in reliance thereon, we are</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the opinion that the Shares, </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when sold and issued against payment therefor in accordance with the Agreement, the Registration Statement and the Prospectus, will be validly issued, fully paid and non</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the reference to our firm under the caption &#8220;<font style="font-weight:bold;">Legal Matters</font>&#8221; in the Prospectus and to the filing of this opinion as an exhibit to the Company&#8217;s Current Report on Form 8-K to be filed with the Commission for incorporation by reference into the Registration Statement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;">Cooley LLP</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:23.08%;">
<tr>
<td valign="top"  style="width:13.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style="width:86.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Brent D. Fassett</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:71.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brent D. Fassett</p></td>
</tr>
</table></div>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP&nbsp;&nbsp; 380 Interlocken Crescent&nbsp;&nbsp; Suite 900&nbsp;&nbsp; Broomfield, CO&nbsp;&nbsp; 80021-8023<br />t: (720) 566-4000&nbsp;&nbsp;f: (720) 566-4099&nbsp;&nbsp;cooley.com</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>abio-ex101_6.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex101_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;"><br />AMENDMENT NO. 1 TO Capital on Demand&#8482; SALES AGREEMENT<br /></font></p>
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">April 6, 2021</font></p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JonesTrading Institutional Services LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757 Third Avenue, 23<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup> Floor</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies and Gentlemen:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc., a Delaware corporation (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Company</font>&#8221;), together with JonesTrading Institutional Services, Inc. (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Agent</font>&#8221;), are parties to that certain Capital on Demand<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Sales Agreement dated July 22, 2020 (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Original Agreement</font>&#8221;). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement.&nbsp;&nbsp;The Company and the Agent desire to amend the Original Agreement as set forth in this Amendment No. 1 thereto (this &#8220;<font style="font-weight:bold;text-decoration:underline;">Amendment</font>) as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">With respect to issuances of Placement Shares that occur on or after the date this Amendment becomes effective, reference to the &#8220;Registration Statement&#8221; in the Original Agreement shall refer to the registration statement on Form S-3 (333-254585), as amended, filed with the Securities and Exchange Commission on March 22, 2021 and declared effective on March 30, 2021 (&#8220;</font><font style="text-decoration:underline;color:#000000;">New Registration Statement</font><font style="font-weight:normal;color:#000000;">&#8221;).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The second paragraph of Section 1 is hereby deleted and replaced as follows:</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:TimesNewRomanPSMT;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;As of the date hereof, the Company has filed or will file a registration statement on Form S-3, in accordance with the provisions of the Securities Act of 1933, as amended (the <font style="font-weight:bold;font-family:TimesNewRomanPS-BoldMT;">&#8220;</font>Securities Act<font style="font-weight:bold;font-family:TimesNewRomanPS-BoldMT;">&#8221;</font>) and the rules and regulations thereunder (the &#8220;Securities Act Regulations<font style="font-weight:bold;font-family:TimesNewRomanPS-BoldMT;">&#8221;</font>), with the Commission, including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the rules and regulations thereunder (the &#8220;Exchange Act Regulations&#8221;). The Company has prepared or will prepare a prospectus included as a part of such registration statement or prospectus supplement to the base prospectus included as part of such registration statement, specifically relating to the Placement Shares (the &#8220;Prospectus Supplement&#8221;). The Company will furnish to the Agent, for use by the Agent, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares. Except where the context otherwise requires, such registration statement, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act Regulations or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act Regulations or any subsequent registration statement on Form S-3 filed pursuant to Rule 415(a)(6) under the Securities Act by the Company to cover </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:TimesNewRomanPSMT;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:TimesNewRomanPSMT;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any securities registered pursuant the Current Registration Statement, including any Placement Shares, as a result of the end of the three-year period described in Rule 415(a)(5) of the Securities Act, is herein called the &#8220;Registration Statement.&#8221; The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act Regulations, together with any then issued Issuer Free Writing Prospectus (defined below), is herein called the &#8220;Prospectus.&#8221; Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein.&#8221;</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section 13 is hereby amended to replace:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;ARCA biopharma, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 140</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Westminster, CO 80020</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Brian Selby&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;ARCA biopharma, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10170 Church Ranch Way, Suite 100</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Westminster, Colorado 80021</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Brian Selby&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All references to &#8220;July 22, 2020&#8221; set forth in Schedule 1 and Exhibit 7(l) of the Original Agreement are revised to read &#8220;July 22, 2020 (as amended by Amendment No. 1, dated April 6, 2021)&#8221;.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:8.65%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as specifically set forth herein, all other provisions of the Original Agreement shall remain in full force and effect.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:8.65%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This Amendment together with the Original Agreement (including all exhibits attached hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Amendment nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent.&nbsp;&nbsp;In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained </font></p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Amendment. All references in the Original Agreement to the &#8220;Agreement&#8221; shall mean the Original Agreement as amended by this Amendment; </font><font style="font-style:italic;color:#000000;">provided, however</font><font style="color:#000000;">, that </font><font style="color:#000000;">all references to &#8220;date of this Agreement&#8221; in the Original Agreement shall continue to refer to the date of the Original Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:8.65%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">EACH OF THE COMPANY (ON ITS BEHALF AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ON BEHALF OF ITS STOCKHOLDERS AND AFFILIATES) AND THE AGENT HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AMENDMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:8.65%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">THIS AMENDMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:8.65%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each of the Company and the Agent agrees that any legal suit, action or proceeding arising out of or based upon this Amendment or the transactions contemplated hereby (&#8220;</font><font style="text-decoration:underline;color:#000000;">Related Proceedings</font><font style="color:#000000;">&#8221;) shall be instituted in (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Specified Courts</font><font style="color:#000000;">&#8221;), and irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any Specified Court, as to which such jurisdiction is non-exclusive) of the Specified Courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to a party&#8217;s address set forth in Section 14 of the Original Agreement, as amended by this Amendment, shall be effective service of process upon such party for any suit, action or proceeding brought in any Specified Court. Each of the Company and the Agent irrevocably and unconditionally waives any objection to the laying of venue of any suit, action or proceeding in the Specified Courts and irrevocably and unconditionally waives and agrees not to plead or claim in any Specified Court that any such suit, action or proceeding brought in any Specified Court has been brought in an inconvenient forum.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:8.65%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed amendment by one party to the other may be made by facsimile transmission or electronic transmission (e.g., PDF).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Remainder of Page Intentionally Blank]</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this Amendment shall constitute a binding amendment to the Original Agreement between the Company and the Agent.&nbsp;&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JONESTRADING INSTITUTIONAL SERVICES LLC</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;&nbsp;&nbsp;&nbsp;&nbsp; <font style="text-decoration:underline;">_/s/ Trent McNair</font>_____________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Trent McNair</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;<font style="margin-left:36pt;"></font>CFO</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:8pt;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">[</font><font style="font-style:italic;font-size:10pt;">Signature Page to Amendment No. 1 to Capital on Demand<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Sales Agreement</font><font style="text-decoration:none;">]</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACCEPTED as of the date</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">first-above written:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">_/s/ Brian Selby</font>_____________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Brian Selby</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Vice President, Finance</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:8pt;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">[</font><font style="font-style:italic;font-size:10pt;">Signature Page to Amendment No. 1 to Capital on Demand<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Sales Agreement</font><font style="text-decoration:none;">]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gaavqm1vj4rf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaavqm1vj4rf000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "* :H# 2(  A$! Q$!_\0
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MU7BW,,'/%ULVQ&'J1AB\'PUE2K8:69SP\G*EB<PK8C"Y7AJ\*V&6)Q..PU?
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MM%EBMH(88+:*XOM3U34[ZXM=*T/0]*M;[6M?UJ^T_1-$T_4-7U"RLI_XB?\
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M-G/_ &&2_P#2('_4)]#S_E&/P8_[(W"_^I6+/]&?]B#_ ),M_9"_[->^ /\
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M^?77U#_P5O\ V0?^&L_V2_$W_",:'_:GQA^#7VOXG_"[[!IGVW7]:_LNR?\
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M_P##8W[6GP_^&&K6GVGX=:!YWQ)^+_[_ ,G?\-?"-[IW]IZ+_HWB/PQKB_\
M";ZYJ7A[X>?VCX7U";7_  U_PEW_  EMO8W-GH%]L_T%J?!F:9_Q!AL5C<QQ
M*H86%6-#"_5<-AZ<ZU6*YJ\I.M2K+V=-2IPBXQ]^HZBYDZ3BX^FCX7^ 'T>>
M).%N"/#OABMGW%&-RVOGW%*XHXDXAQ^"R?+,156&R'"T*62YGDM2.9YA4PV9
M8O$PQ.);PN I9?66&J0S6C6H_P"<Q^V__P GI?M>_P#9T/Q^_P#5K^+*^7J^
MH?VW_P#D]+]KW_LZ'X_?^K7\65\O5^%YC_R,,=_V&8G_ -/3/]W/#K_DWW G
M_9&\,?\ JDP)_HI_L$:'HOA[]B+]D>PT#1]+T.QN/V<O@YKD]EH^GVFF6D^M
M>)_ 6A>)/$FL36UE#!#)JGB'Q%JVJZ_KFH.C7>K:UJ>H:K?S7%]>7,\GUK7R
M]^Q!_P F6_LA?]FO? '_ -51X3KZAK^I\M2678!)))8+"I)*R25"FDDEHDEL
MC_E-\2*M2MXB<>UJU2=6K5XTXIJ5:M24IU*E2>>8Z4ZE2<FY3G.3<I2DW*4F
MVVVPHHHKM/BPHHHH **** "N7\<>-/#7PW\%>+_B'XTU+^QO!W@+POX@\:>+
M-8^QZAJ/]E>&O"VDW>N:[J7]GZ5:WVJ7WV'2[&ZNOL>FV5Y?W/E>19VMQ</'
M"_45^&'_  7W^.]I\//V0=%^"]K<:6_B+]H;QYI.GSZ;J&F:U<79\ ?#"^TO
MQYXDUS0]3LGM]%TS5-,\;6_PLTB:'6YKN74-%\2ZPNE:/<36USJ^@^9G.8QR
MG*\=F,E%_5,/.I",WRQJ5G[F'I2>C2JUY4Z>FOO>ZF[(_3?!CPYQ7BWXJ\!^
M'&%EB:2XKXBP.7X_%8.E[?%8#)82EC,_S.C2<90G/*\CPV89BE52HVPK=><*
M2G./\O?[:W[8'Q _;=^.FK?&CQYIVE^'H8]+MO"/@3P=HZQSVG@KP!I.HZMJ
M>B^'9M9-I9WWB?5%OM<U?5]<\2:E#!+J>M:MJ#:9IOA[P['HGAC1/E[0]#UK
MQ/K6C^&_#>CZIXA\1>(=4T_0] T#0]/N]6UK7-:U:[AL-*T?1]*L(;B^U/5-
M3OKB"RT_3[*">[O+N>&VMH9)I$1LNOZ-/^""W[$?AKXE^)?$/[8GQ#A\+^)M
M#^%?BB\\!?"_P=J5CJ&H7^F?%K3;#P?XME^)MT))K;0X?^$1T/7[*S\%P75K
MXCF?Q+K-YXJ@C\*:YX#\*ZIJW\WY;@L=Q/G4*$JLJF)QM:5;%8FHU>--/GKU
MFK)>Y"_LZ<4HWY*<%&-K?]*WB7QOP+]%[P3QN>8?*J.6\-<$Y-A<FX5X;RZG
M4<<5F$XK!9#D].3E.K_M>,E"689AB:M6NJ/US,L55KUU4E4ZC_@GA_P0UU#Q
M%_8_QA_;@TC['X.UCPNNI>&/V?+;5_$OA_QK-?ZS_:%O;W7Q?O\ 21H.J>#/
M[(TL:?K^F>"_#>O/XEFU;5+&T\=7GA*X\+>(? ?B+]S_ (>?\$V?V#/AAHMU
MH'AK]E+X-:G8WFJ3ZQ+/\0_"EO\ %[6DN[BTLK*2&U\2_%A_&OB*QTM8=/@>
M#0[+5;?1;:[DO;^VT^*^U/4KF[^W:*_H'*N%LDRG#TZ-' 8>M5@GSXO%4*-?
M%59224G*K.#<(NRM2I\E*/2%W)R_YY_%;Z5?CCXN<09AG&=<><19)EF+G36$
MX0X6SO-\CX4RS#X>I4GA:5'*<)CH4L7BJ+JS<\US)XS-,0W%5<6Z-+#T:/Y\
M_$/_ ()4_P#!/;XGZU:Z_P")?V7? >F7UGI<&CQ0?#R]\6?"'17M+>[O;V.:
MZ\-?"?Q'X*\.WVJ--J$Z3ZY>Z5<:U<VD=E87.H2V.F:;;6G\W'_!0_\ X(T_
M$K]E[^V/BG^S[%XH^+_[.VB^%V\0^++S5KO0+OXE?"_^R/[/M==N/$^FZ5::
M!_PEWA>;[3+XFM_$_@[PT/\ A%] M/$(\<Z3HNC^%8_&GBC^TVBL,YX/R3.,
M/.F\'0P6);<Z>-P5"C1KQJ6T=7DA%8BF[)3IU;MQO[.=*;52/O\ @S],CQQ\
M'>(,%F%/B_/.-^&Z4*>#Q_!7&F>YQG625\M51RG2RIXS%XBKPYF$%.<\)F&5
M*$(8A4O[0P>:8&-7+Z_^7O7[3_\ !$W]LS6O@'^TSH7P,\4^(M4_X4Q^T-JD
M7A)= FN;NXT7PY\9=8;3[#X?^,=/TJTT+7+X:IXGOK.Q^%^L#3[CPYI=W:>)
M=#\2>--4N--^'>CI9?.7_!4W]D7PU^QG^UIKWP\\ GR?AEXS\+Z'\4_AMH]Q
MK.H:]JWAGPUXBO=9T._\,ZMJ&HZ=9W#_ -C>,?"WBFU\/":]\17[>"AX8GU[
MQ+J_B6;6IE_.6OP*C5QW#&>*6D<7E>+<*L83?LZT:<N6K2YK)NAB:5XWY5)T
MY\UHRM;_ * LZRK@3Z4'@;4PK4\1P?XH<(TL;E>+Q6$I/,<FKX_#+$97F<<-
M*K4HT<\X<S-4<2J2KU:,,PP,J$JM?#N;J?ZA%%?)7["/QWN_VE_V0?@%\:-5
MN-4OO$7BKP'::?XSU+6-,T71[O6/'_@J^OO ?Q"UR'3/#KMHMGI>N>-O#&OZ
MOH<-A#I\7]BWNGL^CZ),TFD674?M=_'>T_9E_9F^-?QTGN-+M[[X?> ]7U#P
MLFN:9K6KZ+J'C_4UCT#X;Z'K%AX>>#5Y-+\0^/\ 5O#>A:A-;7FF16=IJ,UY
M>ZQHUC;W.JV?]-1Q^'EE\<SY^7"2P:QWM)65L,Z/UCGEKRJU+WG[UEWMJ?\
M,+B. ^),/X@U_#'ZG[?B^AQE5X#_ +/PZJU?;<24L[EP_P#4Z"]C&O4]IF<?
M8TOW"JSO']RIOD/Y/_\ @MQ^VYJ'[0/Q_O?V=_"<WV?X3?LV^*-=T*ZFM+[Q
M+!_PG/Q:BMK/1_&FJ^(-#U*'2M+3_A6^J6NN_#[PA)'I.HS1;O''B'2O%FI^
M'_'MGI^E_B)17Z#?\$R?V/[3]M+]JGPW\.=?U'2[+P!X*TO_ (6S\4+#4#K2
MW?BKP!X5\3^%M*U;P3H;Z#=Z5?6NJ>+[[Q)I6@S:NFNZ)+X<T6^UCQ+87.H:
MOH^G:!K'\RXBOC^)\[E4LIXS,\5&%*FY)4Z49-0HTE)I)4L/248\S7,X0<Y\
MTW)O_IZX=R3@#Z+W@?0P'M)X+@SPRX7K8W-LQCAYU,=FF(P].>+SC-ZF'A4J
M2K9MG^:5:^*6%I5%1CB\93P6$5#"4Z%.E]0_L#_\$8_C+^U1::#\4/C)=ZI\
M#?@)K.EZ#XG\-ZJ;+2]1\?\ Q5T6_P!:V3V_A+0+G45F\%:7J'AVQO\ 4=+\
M?^--)N;2XBU?P=KWA7P;\0?#.L7M_IO]+?P\_P""5/\ P3V^&&M76O\ AK]E
MWP'J=]>:7/H\L'Q#O?%GQ>T5+2XN[*]DFM?#7Q8\1^-?#MCJBS:? D&N66E6
M^M6UI)>V%MJ$5CJ>I6UW]Y:'H>B^&-%T?PWX;T?2_#WAWP]I>GZ'H&@:'I]I
MI.BZ'HNDVD-AI6CZ/I5A#;V.F:7IEC;P66GZ?9006EG:00VUM#'#&B+J5^]Y
M+P=DF3X>G'ZG0QN*M"57&8RE3Q%5U4G=T%4@XX>FG*2C&E&,G!1]K.K./._\
M _&OZ9?C?XQ<08[%+C'/."^%'/%8;*>#^#LUS+A_+*>5U:E+V4,[E@,;#$<1
M9A4IX>A5Q6(S;$8K#TL7/%/*,)E>#K_4X_$7Q#_X)L_L&?$_1;70/$O[*7P:
MTRQL]4@UB*?X>>%+?X0ZT]W;VE[91PW7B7X3OX*\17VEM#J$[SZ'>ZK<:+<W
M<=E?W.GRWVF:;<VGXL?MW?\ !!C_ )"/Q)_877_H6K2;]F_Q!K?_ %VTW7O$
M'@?XI>/O%?\ V!]:N_"'CJ__ .AOU'1O''_(K?#VOZA**Z\SX6R+-:,Z6(R_
M#TYS2Y<5A:-+#XNFTFHRA7A3O)1YFU3JJI1;2<Z4K*WRGAC]*CQW\)\ZP6:\
M.^(?$698+"3DZ_"W%.;YKQ%PCF-&K6HUL30Q>1X['.E0GB70A3GF655,MSJC
M2E5C@\SPWMJCE_F%ZYH>M>&-:UCPWXDT?5/#WB+P]JFH:'K^@:YI]WI.M:'K
M6DW<UAJNCZQI5_#;WVF:IIE];SV6H:?>P07=G=P36US#'-&Z+[S^RA^TS\0/
MV1_CIX'^-GP_U#5(YO#VJ64'B_PWI^JQZ3:?$3P!/J-C<^+/AYKD]UIFN6*Z
M7XGL;-8(;V[T/5I?#FM0:/XNT>UC\1>'M&O;3]I_^"]/[$?AKX:>)?#W[8GP
M\A\+^&=#^*GBBS\!?%#P=IMCJ&GW^I_%K4K#QAXMB^)MJ(YKG0YO^$NT/0+V
MS\:06MKX<F3Q+HUGXJGC\5ZYX\\5:II/\Y=?SUFF QO#6<U,-[25/$8.M"MA
M<33=G*%U4P]>+6TG&SE%_#-2@[VU_P"B3PLX_P""OI+^#.7\1O+:./X>XSR;
M&9+Q3PYF-&4Z6'QWLI9?Q%D6)C*SJT:5=UH8;%0DGB,)/#8VE*G*I'D_TX/
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MW?B3IG[_ ,O^T/AK<V5G_P +?T7_ $[Q'HNAVGV30]%TGXA_VC<:?K^OS_\
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MVBZYHNK6DUAJNCZQI5_#<6.IZ7J=C<3V6H:?>P3VEY:3S6US#)#(Z-_G^_\
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M&K?Q9\>_BGX7^&^EWWF_V/:ZK/<WWB7Q']EO]&TW4/\ A$_!>AVVJ>,?%O\
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MM?M5_L8^-O#?A"/5+[Q_\,-4L_C7X#T#2TN[F7Q9K7@K1]?L-7\*#2M,\/\
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MO3RF']:E?.7[3'[5_P "_P!D?P!J'Q ^-GCC2_#T,>EZKJ'AOPA!>Z=/X_\
MB)=Z3+IEK/H?P\\)W-]9WWB?5%OM<T.TO9H&@T7PY%JUKK'B[6/#WAV.]UFT
M_FC^(?\ P<6?M":GK5K/\)_@#\&O!7AU-+@AO=*^(>I^-OB?K5QK2W=Z]SJ%
MKK_AO5_A%8V>ERV,FFVT&CR^&[Z[M[NTO;V37+F'4(+#3/PQ^+_QL^+7Q^\:
MWWQ#^,_Q!\4?$CQC??:8_P"V/$^IS7W]FV%UJVIZY_87A[3\II?A?PO9ZIK.
MJW6D^$_#=EI7AK1/MUQ!H^E6-N_DC#.?$K+:%"<,FA/&XJ7-&%:M2J4<-2VM
M4E"HH5JM[OEI\M/6+<Y15E+W/!C]F7XDYYGF$QGC3B\'P3POAOJ^(QN3Y-FN
M79WQ/FO-*K[7+:&+R^>.R;*N14Z?UC,)8C,N6%>$<)A:\_:U,,?&OXO^-?C]
M\6OB#\9_B'??;O&/Q(\4:IXGUCR[G5KJPTW[=,?[/\/:%_;FIZSJEGX7\+:6
MEEX;\)Z3=:K??V)X:TK2M'@N'M[&'&5\,/AA\0/C1X_\*_"SX6^%=4\:^/\
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M5M%US1=6M)K#5='UC2K^&XL=3TO4[&XGLM0T^]@GM+RTGFMKF&2&1T;^:/\
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M9J-# 93@'7JXBGEF48"BHX? 8"C4K5)0HTH<]2<I5\35KXFI5K3****]$_.
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M%CJ>EZG8W$]EJ&GWL$]I>6D\UM<PR0R.C?.7_#$'[%O_ $:%^R]_X8#X4?\
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MJ/\ 9FM?Z3X<\3Z&W_"$:'IOB'XA_P!G>)]/AT#Q+_PB/_")7%_;7FOV._\
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MO_K!G$L=F>'Q2A&O+**F4X*NY_4*;11117U9_)84444 %%%% !1110 4444
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E%CZT\OE"O2CAL5"A62E&E[.7J%%%%?NY_@F%%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
